ArticleFrontiers in oncology2026
Development and validation of a nomogram for predicting moderate-to-severe complications following primary tumor resection in metastatic colorectal cancer.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Colorectal cancer has high incidence and mortality. Surgery is the primary curative treatment, but postoperative complications remain common. This study developed and validated a nomogram to predict moderate-to-severe complications after primary tumor resection(PTR) in metastatic colorectal cancer (mCRC). Method: A retrospective analysis of clinical data was conducted for mCRC patients undergoing PTR at our institution between January 2022 and December 2024. All patients were randomly divided into two groups: 70% for development and 30% for validation. Univariate and multivariate logistic regression analyses were conducted to identify the independent risk factors associated with moderate-to-severe complications occurring within 30 days postoperatively. Correlation heatmaps and Lasso regression analysis were employed to systematically screen and identify the most relevant variables. Subsequently, a nomogram was developed based on the significant predictors. The area under the curve (AUC) was determined based on the receiver operating characteristic (ROC) curve for assessing the predictive probability. A calibration curve was generated to contrast the predicted probability against the observed probability. The clinical utility of the nomogram was evaluated using decision curve analysis (DCA). Internal 10-fold cross-validation was performed using bootstrapping, and boxplots as well as the average calibration curve were generated to visualize the results. Results: A total of 404 mCRC patients receiving PTR treatment were enrolled, including 282 in the development group and 122 in the validation group. Of these, 32% (90) in the development group and 39% (47) in the validation group experienced moderate-to-severe postoperative complications. Multivariate Logistic regression analysis identified age (p = 0.017, OR = 1.041, 95% CI: 1.007-1.076), preoperative albumin level (p < 0.001, OR = 0.774, 95% CI: 0.704-0.851), tumor location (p = 0.012, OR = 2.243, 95% CI: 1.216-4.906), and operation duration (p < 0.001, OR = 1.007, 95% CI: 1.003-1.011) as independent risk factors for moderate-to-severe complications after PTR surgery. Based on these findings, a nomogram was developed and validated. Conclusion: This study identified four independent risk factors for moderate-to-severe complications in mCRC patients after PTR surgery and developed a reliable predictive model to assist surgeons in optimizing perioperative management for high-risk cases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.